NS-2359
As of the edition of 20 October 2026, NS-2359 is a small molecule: went quiet in 2020; acts on SLC6A2, SLC6A3 and SLC6A4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Small molecule
- Registered trials
- 7, 0 stopped early
- Disease areas
- Mental health; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 3 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of NS-2359.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product3 company-target rows are on route A because of NS-2359.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| NeuroSearch A/S | Lead sponsor of trials | 2003 to now |
| GSK | Lead sponsor of trials | 2006 to now |